Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samotolisib + Necitumumab in Metastatic Squamous NSCLC
NCT02443337Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of samotolisib in squamous cell carcinoma of the lung (SCCL), sponsored by Eli Lilly and Company. Started Jul 2015; status: terminated.
02
Drugs
samotolisib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02443337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443337.